Evidence map›Paper›PMID 25203266›Full record

ArticlePloS one2014

Antibodies to the extracellular pore loop of TRPM8 act as antagonists of channel activation.

Silke Miller, Sara Rao, Weiya Wang, Hantao Liu, Judy Wang, Narender R Gavva

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Pathology of pain and its implications for therapeutic interventions.Signal transduction and targeted therapy · 2024
    Review
  4. Review
  5. TRPM8 and prostate: a cold case?Pflugers Archiv : European journal of physiology · 2018
    Review
  6. Article
  7. Review
  8. Article
  9. TRPM8 and Migraine.Headache · 2016
    Review
  10. TRPM8 Puts the Chill on Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2016
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Silke MillerDepartment of Neuroscience, Amgen Inc., Thousand Oaks, California, United States of America.
Sara RaoDepartment of Neuroscience, Amgen Inc., Thousand Oaks, California, United States of America.
Weiya WangDepartment of Neuroscience, Amgen Inc., Thousand Oaks, California, United States of America.
Hantao LiuDepartment of Neuroscience, Amgen Inc., Thousand Oaks, California, United States of America.
Judy WangDepartment of Neuroscience, Amgen Inc., Thousand Oaks, California, United States of America.
Narender R GavvaDepartment of Neuroscience, Amgen Inc., Thousand Oaks, California, United States of America.
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mammalian transient receptor potential melastatin channel 8 (TRPM8) is highly expressed in trigeminal and dorsal root ganglia. TRPM8 is activated by cold temperature or compounds that cause a cooling sensation, such as menthol or icilin. TRPM8 may play a role in cold hypersensitivity and hyperalgesia in various pain syndromes. Therefore, TRPM8 antagonists are pursued as therapeutics. In this study we explored the feasibility of blocking TRPM8 activation with antibodies. We report the functional characterization of a rabbit polyclonal antibody, ACC-049, directed against the third extracellular loop near the pore region of the human TRPM8 channel. ACC-049 acted as a full antagonist at recombinantly expressed human and rodent TRPM8 channels in cell based agonist-induced 45Ca2+ uptake assays. Further, several poly-and monoclonal antibodies that recognize the same region also blocked icilin activation of not only recombinantly expressed TRPM8, but also endogenous TRPM8 expressed in rat dorsal root ganglion neurons revealing the feasibility of generating monoclonal antibody antagonists. We conclude that antagonist antibodies are valuable tools to investigate TRPM8 function and may ultimately pave the way for development of therapeutic antibodies.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalCell LineCHO CellsCold TemperatureCricetulusGanglia, SpinalHumansHyperalgesiaMaleMolecular Sequence DataNeuronsRatsRats, Sprague-DawleyTRPM Cation ChannelsAntibodies, MonoclonalTRPM Cation Channels

Identifiers

PMID25203266
PMCPMC4159296
OpenAlexW2012649101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.